<DOC>
	<DOCNO>NCT00948493</DOCNO>
	<brief_summary>The objective Treatment IND protocol provide Generex Oral-lyn™ patient serious life-threatening Type 1 Type 2 diabetes mellitus , satisfactory alternative therapy available treatment diabetes , eligible participate ongoing pivotal clinical trial ( Protocol GEN-084-OL ) . This protocol intend substitute Single Patient IND mechanism obtain Generex Oral-lyn™ .</brief_summary>
	<brief_title>Treatment Use Generex Oral-lyn™ Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Study close</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin therapy</keyword>
</DOC>